Li et al., 2022 - Google Patents

Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease

Li et al., 2022

View HTML
Document ID
10811157861680508726
Author
Li Y
Fan W
Link F
Wang S
Dooley S
Publication year
Publication venue
JHEP Reports

External Links

Snippet

Transforming growth factor-β (TGF-β) is a potent effector in the liver, which is involved in a plethora of processes initiated upon liver injury. TGF-β affects parenchymal, non- parenchymal, and inflammatory cells in a highly context-dependent manner. Its …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans

Similar Documents

Publication Publication Date Title
Li et al. Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease
Mott et al. Regulation of matrix biology by matrix metalloproteinases
US20090017019A1 (en) Methods and compositions for modulating bmp-10 activity
Rodríguez et al. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics
Gressner et al. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases
Saharinen et al. Latent transforming growth factor-β binding proteins (LTBPs)—structural extracellular matrix proteins for targeting TGF-β action
Shi-Wen et al. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis
Nyberg et al. Tumor microenvironment and angiogenesis
AU784338B2 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
Zhu et al. Periostin promotes ovarian cancer angiogenesis and metastasis
Bonnefoy et al. Thrombospondins: from structure to therapeutics: The evolving role of thrombospondin-1 in hemostasis and vascular biology
US7387779B2 (en) Anti-angiogenic proteins and fragments and methods of use thereof
US20080241835A1 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
AU6085700A (en) Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
JP2006507356A (en) Myostatin metalloprotease activation and method of modulating myostatin activity
Carpizo et al. Endogenous regulators of angiogenesis–emphasis on proteins with thrombospondin–type I motifs
Wu et al. Isolation of a novel basic FGF‐binding peptide with potent antiangiogenetic activity
US7378396B2 (en) Therapeutic agents and methods for cardiovascular disease
Aykul et al. New ligand binding function of human cerberus and role of proteolytic processing in regulating ligand–Receptor interactions and antagonist activity
JP2009019032A (en) Promotion or inhibition of angiogenesis and cardiovascularization
JP2004513066A (en) Angiosidine: CYS-SER-VAL-THR-CYS-GLY specific tumor cell adhesion receptor
JP4654029B2 (en) Single domain TDF related compounds and analogs thereof
JP2014529605A (en) Means and methods for treating angiogenesis-related diseases
US20020123091A1 (en) Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
Fang Mesenchymal regulation of alveolar repair in pulmonary fibrosis